ETHOS ENGAGE: Enhancing Treatment of Hepatitis C in Opioid Substitution Settings
ConditionHepatitis C
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorKirby Institute
About this trial
The overall goals of the ETHOS II Project are to enhance hepatitis C virus (HCV) care in drug treatment clinics and needle and syringe programs (NSPs) in New South Wales and Australia, and to develop a translational framework for subsequent establishment of HCV screening and treatment programs in drug treatment clinics and NSPs across NSW and nationally.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Participant has voluntarily signed the informed consent form;
18 years of age or older;
History of injecting drug use*;
Recent injecting drug use (previous six months) or currently receiving OST*.
Disqualifiers
Nil
Trial design
Design model
Single group
Treatments tested in this trial
Campaign days
Procedure/SurgeryParticipants who consent will complete study procedures (Hep C test, fibroscan, questionnaire, clinical assessment) and followed up through medical record review.
Treatment groups
6,000 Participants
are divided into 1 treatment groupGroup A: Campaign DaysExperimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
Number of participants commencing anti-HCV treatment
Evaluation of number of participants commencing anti-HCV treatment
Time frame
Every year post enrolment for up to 3 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Kirby Institute
Lead sponsor
National Health and Medical Research Council, Australia
Collaborator
Source ClinicalTrials.gov